BiotechTube
Adiposs

Adiposs

Lausanne, Switzerland· Est.
adiposs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Adiposs is pioneering a novel diagnostic imaging platform focused on brown adipose tissue (BAT), a metabolically active fat with significant implications for metabolic diseases and oncology. Its lead candidate, ImageBAT™, is a first-in-class contrast agent that has completed a Phase I clinical trial and is poised for proof-of-principle studies following a CHF 4 million Series A round. The company, led by an experienced team of biotech entrepreneurs, is targeting a significant unmet need in functional metabolic imaging, with potential applications in patient stratification, treatment monitoring, and therapeutic development across multiple disease areas.

OncologyMetabolic DiseasesNeurology

Technology Platform

Platform for developing targeted contrast agents, specifically ImageBAT™, a first-in-class radiopharmaceutical for PET imaging of brown adipose tissue (BAT) activity.

Opportunities

The primary opportunity is to establish ImageBAT™ as the standard-of-care diagnostic for assessing metabolic health via brown fat imaging, creating a new biomarker market.
In oncology, it offers a novel tool for prognostic stratification, which could guide treatment decisions and be integrated into clinical trials for metabolic-oncology therapies.
The platform's applicability across multiple disease areas provides multiple shots on goal for value creation.

Risk Factors

The major risk is the unproven clinical utility of brown fat imaging as a robust prognostic or diagnostic biomarker in intended diseases.
Regulatory pathways for first-in-class diagnostic radiopharmaceuticals can be complex and uncertain.
Finally, market adoption may be slow, requiring significant education of clinicians and demonstration of cost-effectiveness to secure reimbursement.

Competitive Landscape

Adiposs appears to be first-in-class with a targeted BAT imaging agent, facing little direct competition. However, indirect competition exists from companies developing therapies that modulate BAT activity or from alternative metabolic imaging approaches (e.g., FDG-PET used off-label). Larger diagnostic imaging firms could enter the space if the clinical utility is proven.

More companies in Switzerland →